HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ranibizumab(Lucentis) in high myopia with neovascularization. Better short-term visual acuity but serious adverse effects.

Abstract
In a trial versus verteporfin photodynamic therapy, ranibizumab improved visual acuity after 3 months of treatment but had more adverse effects.
Authors
JournalPrescrire international (Prescrire Int) Vol. 24 Issue 161 Pg. 151 (Jun 2015) ISSN: 1167-7422 [Print] France
PMID26436164 (Publication Type: Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab
Topics
  • Angiogenesis Inhibitors (adverse effects)
  • Antibodies, Monoclonal, Humanized (adverse effects)
  • Choroidal Neovascularization (diagnosis, drug therapy, physiopathology)
  • Humans
  • Myopia (diagnosis, drug therapy, physiopathology)
  • Ranibizumab
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Visual Acuity (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: